Cargando…

HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?

BACKGROUND: Significant quantities of antiretroviral drugs (ARVs) to treat HIV/AIDS have been procured for Sub-Saharan Africa for the first time in their 20-year history. This presents a novel opportunity to empirically study the roles of brand and generic suppliers in providing access to ARVs. METH...

Descripción completa

Detalles Bibliográficos
Autor principal: Chien, Colleen V.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805689/
https://www.ncbi.nlm.nih.gov/pubmed/17372625
http://dx.doi.org/10.1371/journal.pone.0000278
_version_ 1782132487137263616
author Chien, Colleen V.
author_facet Chien, Colleen V.
author_sort Chien, Colleen V.
collection PubMed
description BACKGROUND: Significant quantities of antiretroviral drugs (ARVs) to treat HIV/AIDS have been procured for Sub-Saharan Africa for the first time in their 20-year history. This presents a novel opportunity to empirically study the roles of brand and generic suppliers in providing access to ARVs. METHODOLOGY/PRINCIPAL FINDINGS: An observational study of brand and generic supply based on a dataset of 2,162 orders of AIDS drugs for Sub-Saharan Africa reported to the Global Price Reporting Mechanism at the World Health Organization from January 2004-March 2006 was performed. Generic companies supplied 63% of the drugs studied, at prices that were on average about a third of the prices charged by brand companies. 96% of the procurement was of first line drugs, which were provided mostly by generic firms, while the remaining 4%, of second line drugs, was sourced primarily from brand companies. 85% of the generic drugs in the sample were manufactured in India, where the majority of the drugs procured were ineligible for patent protection. The remaining 15% was manufactured in South Africa, mostly under voluntary licenses provided by brand companies to a single generic company. In Sub-Saharan African countries, four first line drugs in the dataset were widely patented, however no general deterrent to generic purchasing based on a patent was detected. CONCLUSIONS/SIGNIFICANCE: Generic and brand companies have played distinct roles in increasing the availability of ARVs in Sub-Saharan Africa. Generic companies provided most of the drugs studied, at prices below those charged by brand companies, and until now, almost exclusively supplied several fixed-dose combination drugs. Brand companies have supplied almost all second line drugs, signed voluntary licenses with generic companies, and are not strictly enforcing patents in certain countries. Further investigation into how price reductions in second line drugs can be achieved and the cheapest drugs can actually be procured is warranted.
format Text
id pubmed-1805689
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-18056892007-03-19 HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare? Chien, Colleen V. PLoS One Research Article BACKGROUND: Significant quantities of antiretroviral drugs (ARVs) to treat HIV/AIDS have been procured for Sub-Saharan Africa for the first time in their 20-year history. This presents a novel opportunity to empirically study the roles of brand and generic suppliers in providing access to ARVs. METHODOLOGY/PRINCIPAL FINDINGS: An observational study of brand and generic supply based on a dataset of 2,162 orders of AIDS drugs for Sub-Saharan Africa reported to the Global Price Reporting Mechanism at the World Health Organization from January 2004-March 2006 was performed. Generic companies supplied 63% of the drugs studied, at prices that were on average about a third of the prices charged by brand companies. 96% of the procurement was of first line drugs, which were provided mostly by generic firms, while the remaining 4%, of second line drugs, was sourced primarily from brand companies. 85% of the generic drugs in the sample were manufactured in India, where the majority of the drugs procured were ineligible for patent protection. The remaining 15% was manufactured in South Africa, mostly under voluntary licenses provided by brand companies to a single generic company. In Sub-Saharan African countries, four first line drugs in the dataset were widely patented, however no general deterrent to generic purchasing based on a patent was detected. CONCLUSIONS/SIGNIFICANCE: Generic and brand companies have played distinct roles in increasing the availability of ARVs in Sub-Saharan Africa. Generic companies provided most of the drugs studied, at prices below those charged by brand companies, and until now, almost exclusively supplied several fixed-dose combination drugs. Brand companies have supplied almost all second line drugs, signed voluntary licenses with generic companies, and are not strictly enforcing patents in certain countries. Further investigation into how price reductions in second line drugs can be achieved and the cheapest drugs can actually be procured is warranted. Public Library of Science 2007-03-14 /pmc/articles/PMC1805689/ /pubmed/17372625 http://dx.doi.org/10.1371/journal.pone.0000278 Text en Colleen Chien. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Chien, Colleen V.
HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?
title HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?
title_full HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?
title_fullStr HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?
title_full_unstemmed HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?
title_short HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?
title_sort hiv/aids drugs for sub-saharan africa: how do brand and generic supply compare?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805689/
https://www.ncbi.nlm.nih.gov/pubmed/17372625
http://dx.doi.org/10.1371/journal.pone.0000278
work_keys_str_mv AT chiencolleenv hivaidsdrugsforsubsaharanafricahowdobrandandgenericsupplycompare